I-Mab (IMAB)
Chart Events
Performance Outlook
| Previous Close | 57.50 |
| Open | 57.09 |
| Bid | 58.61 x 1200 |
| Ask | 58.81 x 900 |
| Day's Range | 55.74 - 59.48 |
| 52 Week Range | 11.05 - 65.55 |
| Volume | 291,965 |
| Avg. Volume | 273,770 |
| Market Cap | 4.203B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | Aug 31, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 69.10 |
- PR Newswire
I-Mab Announces Upcoming Participation at March Conferences
I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conferences in March. Details of the conferences and management presentation are as follows:
- PR Newswire
I-Mab Announces China NMPA Clearance for Phase 1 Study of TJ210/MOR210 in Patients with Advanced Solid Tumors
I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has cleared the Investigational New Drug (IND) application for TJ210/MOR210 to initiate a phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of TJ210/MOR210 monotherapy in patients with advanced solid tumors.
- PR Newswire
Registered Secondary Public Offering of American Depositary Shares by Certain Pre-IPO Shareholders of I-Mab Has Priced
A registered follow-on public offering by certain pre-IPO shareholders (the "Selling Shareholders") of 3,283,950 American depositary shares (the "ADSs" and such offering, the "ADS Offering") of I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, has priced on February 8, 2021 at a public offering price of US$54.0 per ADS. The underwriters in the ADS Offering will have a 30-day option to purchase up to 492,590 additional ADSs from certain Selling Shareholders. Each ten (10) ADSs represent twenty-three (23) ordinary shares of the Company.
